---
title: "SHARES Investor Evenings"
publisher: "Share Talk"
author: "sharetalk"
published: "2016-05-10T10:48:38+00:00"
modified: "2017-09-01T14:14:08+00:00"
date: 2016-05-10
canonical: "https://www.share-talk.com/shares-investor-evenings/"
category: "Investment Events"
categories: ["Investment Events"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# SHARES Investor Evenings

**Published:** May 10, 2016
**Author:** sharetalk
**Categories:** Investment Events
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1)

---

### ![](http://i1.cmail20.com/ei/r/72/D8B/B16/181208/csimport/investoreveningheader02_0.jpg)

### Network with the CEOs and directors of AB Dynamics,  Evgen Pharma, Silence Therapeutics and Valirx in London on 19th May

The SHARES Investor Evenings are designed to showcase a number of presentations from dynamic companies to discuss their latest plans regarding development and growth.

This gives you the opportunity to meet and ask questions directly to the leaders of the companies presenting.

**Date:** 19th May 2016, **Location:** Novotel Tower Bridge, 10 Pepys Street, London, EC3N 2NR, **Registration:** 18:00, **Presentations:** 18:30, Followed by drinks and canapés

### Companies presenting

Tim Rogers, MD – AB Dynamics (ABDP)

Anthony Best Dynamics supplies advanced testing systems to the global motor industry, for research and development and for production quality control. They design and manufacture specialised systems for Kinematics and compliance testing, vehicle dynamics testing on the track, Vehicle Dynamics/Driver in Loop Simulation, Driver assistance system (ADAS) testing, autonomous vehicle testing, steering system testing and noise/vibration (NVH) testing of powertrain assemblies.

Ali Mortazavi, CEO – Silence Therapeutics (SLN)

Silence Therapeutics is a leading RNA technology company. They are a drug development company with a proprietary genetic medicine platform. Their technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo. Silence Therapeutics have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics.

Dr. George Morris, COO – Valirx (VAL)

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers.

Stephen Franklin, Chief Executive – Evgen Pharma (EVG)

Evgen Pharma is a clinical stage drug development company focused on cancer and neurological disease. Their pipeline is based on their proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Evgen Pharma’s objective is to become the leading company in the development of pharmaceuticals that activate the antioxidant response element, Nrf2.

[Book My Complimentary Ticket](http://www.sharesmagazine.co.uk/events/event/shares-investor-evening-19-May-2016)

---

**Original URL:** https://www.share-talk.com/shares-investor-evenings/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*